JP2007508260A5 - - Google Patents

Info

Publication number

JP2007508260A5

JP2007508260A5 JP2006530088A JP2006530088A JP2007508260A5 JP 2007508260 A5 JP2007508260 A5 JP 2007508260A5 JP 2006530088 A JP2006530088 A JP 2006530088A JP 2006530088 A JP2006530088 A JP 2006530088A JP 2007508260 A5 JP2007508260 A5 JP 2007508260A5

Authority

JP

Japan

Prior art keywords

phenyl

propyl

difluorophenoxy

chloro

amide

Prior art date

2004-10-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 125000001072 heteroaryl group Chemical group 0.000 claims 6
• VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims 5
• 229910052739 hydrogen Inorganic materials 0.000 claims 5
• 239000001257 hydrogen Substances 0.000 claims 5
• 125000000217 alkyl group Chemical group 0.000 claims 4
• 150000001875 compounds Chemical class 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 4
• -1 8- {4- [3- (2-Chloro-3,6-difluorophenoxy) propyl] phenyl} -5-aza-spiro [2.5] -7-octene-7-carboxylate cyclopropyl- (2, 3-dichlorobenzyl) amide Chemical compound 0.000 claims 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
• 125000003118 aryl group Chemical group 0.000 claims 3
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
• 206010019280 Heart failures Diseases 0.000 claims 2
• 125000002947 alkylene group Chemical group 0.000 claims 2
• 125000000753 cycloalkyl group Chemical group 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 150000002431 hydrogen Chemical class 0.000 claims 2
• 230000002792 vascular Effects 0.000 claims 2
• KZRLJNKWCZPQKO-UHFFFAOYSA-N 4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-[(2,3-dichlorophenyl)methyl]-5,5-difluoro-2,6-dihydro-1h-pyridine-3-carboxamide Chemical compound FC1=CC=C(F)C(OCCCC=2C=CC(=CC=2)C=2C(CNCC=2C(=O)N(CC=2C(=C(Cl)C=CC=2)Cl)C2CC2)(F)F)=C1Cl KZRLJNKWCZPQKO-UHFFFAOYSA-N 0.000 claims 1
• NHKGQZOIJVMGNE-UHFFFAOYSA-N 4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-[(2,3-dichlorophenyl)methyl]-5,5-dimethyl-2,6-dihydro-1h-pyridine-3-carboxamide Chemical compound C=1C=C(CCCOC=2C(=C(F)C=CC=2F)Cl)C=CC=1C=1C(C)(C)CNCC=1C(=O)N(C1CC1)CC1=CC=CC(Cl)=C1Cl NHKGQZOIJVMGNE-UHFFFAOYSA-N 0.000 claims 1
• UGPQRQQXVSPLPN-UHFFFAOYSA-N 4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-[(2-methoxy-3-methylpyridin-4-yl)methyl]-5,5-dimethyl-2,6-dihydro-1h-pyridine-3-carboxamide Chemical compound COC1=NC=CC(CN(C2CC2)C(=O)C=2CNCC(C)(C)C=2C=2C=CC(CCCOC=3C(=C(F)C=CC=3F)Cl)=CC=2)=C1C UGPQRQQXVSPLPN-UHFFFAOYSA-N 0.000 claims 1
• ONXNDFLMHFUDGB-UHFFFAOYSA-N 4-[4-[3-(2-chloro-3,6-difluorophenoxy)propyl]phenyl]-n-cyclopropyl-n-[[2-(2-hydroxypropoxy)-3-methylpyridin-4-yl]methyl]-5,5-dimethyl-2,6-dihydro-1h-pyridine-3-carboxamide Chemical compound CC(O)COC1=NC=CC(CN(C2CC2)C(=O)C=2CNCC(C)(C)C=2C=2C=CC(CCCOC=3C(=C(F)C=CC=3F)Cl)=CC=2)=C1C ONXNDFLMHFUDGB-UHFFFAOYSA-N 0.000 claims 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
• 208000019901 Anxiety disease Diseases 0.000 claims 1
• 201000001320 Atherosclerosis Diseases 0.000 claims 1
• 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
• 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
• 208000006029 Cardiomegaly Diseases 0.000 claims 1
• 208000031229 Cardiomyopathies Diseases 0.000 claims 1
• 208000028698 Cognitive impairment Diseases 0.000 claims 1
• 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
• 208000010412 Glaucoma Diseases 0.000 claims 1
• 206010018364 Glomerulonephritis Diseases 0.000 claims 1
• 206010020571 Hyperaldosteronism Diseases 0.000 claims 1
• 206010020772 Hypertension Diseases 0.000 claims 1
• 208000012902 Nervous system disease Diseases 0.000 claims 1
• 208000025966 Neurological disease Diseases 0.000 claims 1
• 208000001647 Renal Insufficiency Diseases 0.000 claims 1
• 206010038419 Renal colic Diseases 0.000 claims 1
• 206010063897 Renal ischaemia Diseases 0.000 claims 1
• 206010039710 Scleroderma Diseases 0.000 claims 1
• 239000002671 adjuvant Substances 0.000 claims 1
• 125000003342 alkenyl group Chemical group 0.000 claims 1
• 125000004450 alkenylene group Chemical group 0.000 claims 1
• 125000000304 alkynyl group Chemical group 0.000 claims 1
• 238000002399 angioplasty Methods 0.000 claims 1
• 230000036506 anxiety Effects 0.000 claims 1
• 230000009787 cardiac fibrosis Effects 0.000 claims 1
• 238000007675 cardiac surgery Methods 0.000 claims 1
• 208000010877 cognitive disease Diseases 0.000 claims 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 229940079593 drug Drugs 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 230000004406 elevated intraocular pressure Effects 0.000 claims 1
• 229910052731 fluorine Inorganic materials 0.000 claims 1
• 239000011737 fluorine Substances 0.000 claims 1
• 125000000623 heterocyclic group Chemical group 0.000 claims 1
• 229960003444 immunosuppressant agent Drugs 0.000 claims 1
• 230000001861 immunosuppressant effect Effects 0.000 claims 1
• 239000003018 immunosuppressive agent Substances 0.000 claims 1
• 201000001881 impotence Diseases 0.000 claims 1
• 208000017169 kidney disease Diseases 0.000 claims 1
• 201000006370 kidney failure Diseases 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
• 230000000877 morphologic effect Effects 0.000 claims 1
• 208000031225 myocardial ischemia Diseases 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
• XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 claims 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
• 208000002815 pulmonary hypertension Diseases 0.000 claims 1
• 201000002793 renal fibrosis Diseases 0.000 claims 1
• 230000036454 renin-angiotensin system Effects 0.000 claims 1
• 208000037803 restenosis Diseases 0.000 claims 1
• 150000003839 salts Chemical class 0.000 claims 1
• 239000002904 solvent Chemical class 0.000 claims 1
• 208000019553 vascular disease Diseases 0.000 claims 1
• 238000007631 vascular surgery Methods 0.000 claims 1
• 0 CC1=C(**N)CNCC1(*)* Chemical compound CC1=C(**N)CNCC1(*)* 0.000 description 1